I was recently diagnosed with anti-NMDA receptor encephalitis

Original Article ↗ Hacker News Discussion ↗

Overall reaction & support

  • Many express empathy, relief at the good prognosis, and gratitude for the write‑up and prior open‑source work.
  • Several note how eye‑opening it is that such severe, surreal symptoms can come from a treatable, relatively new diagnosis.

Misdiagnosis, psychiatry, and the healthcare system

  • Multiple stories describe serious conditions (autoimmune disease, diabetes, spinal injury, gallbladder rupture, encephalitis, lupus, etc.) initially dismissed as anxiety, “in your head,” or minor issues.
  • Commenters highlight how a prior psychiatric label can anchor later clinicians toward psych explanations and away from neurology.
  • Some clinicians in the thread acknowledge time pressure, cognitive bias, and the difficulty of recognizing rare “zebras” among many benign complaints.
  • Others emphasize systemic issues: short visit times, fragmented records, SES and gender biases, and the need for a strong patient advocate or “wingman.”

Autoimmune and rare disorders

  • Many share experiences with autoimmune or rare conditions: anti-NMDA encephalitis variants, MCAS, EGPA, LADA, ME/CFS, long‑COVID, paraneoplastic syndromes, etc.
  • Common themes: years of misdiagnosis, vague multisystem symptoms, overlapping psychiatric features, and partial or delayed recovery.
  • Some note associated tumors or idiopathic cases; others mention coexisting autoimmune diseases and family history.

Imaging, diagnostics, and AI tools

  • Several argue for aggressive imaging (e.g., MRI) for unexplained neuro/psych symptoms; others caution about overtesting and finite resources.
  • There is strong interest in better diagnostic technology (including AI “tricorder‑like” tools) to reduce human bias.
  • Some report LLMs helping them or relatives converge on likely diagnoses (e.g., withdrawal syndromes, MCAS, POTS, EDS) and treatment trials; others report AI being unhelpful or confusing.
  • Consensus: AI is valuable as a second opinion and research assistant, but not a replacement for clinicians.

Research, treatment, and biomedical progress

  • Commenters stress that anti‑NMDA receptor encephalitis was only characterized in 2007, illustrating how new entities can reframe what was once “just schizophrenia.”
  • There is praise for IVIG/monoclonal antibody therapies and rapid vaccine development as under‑appreciated biomedical successes.
  • Some call for a “tech‑like boom” in biomedicine, while others note constraints from regulation, clinical trial realities, and the inherent complexity of biology.

Mortality, fragility, and life changes

  • Statistical back‑of‑the‑envelope calculations about HN reader mortality spur reflection on how fragile health is.
  • Several mention that severe illness reshapes priorities, relationships, and appreciation for everyday life.